Mustang Bio: MB-106 achieves 100% complete response in follicular lymphoma in Phase 1/2

MUSTANG BIO, INC.

100% complete response rate in 5 follicular lymphoma patients; 100% overall response in follicular and Waldenstrom macroglobulinemia.
Favorable safety: no CRS > Grade 1, no ICANS; outpatient administration feasible.
Complete responses seen in patients previously treated with CD19-targeted CAR-T therapy.
Plan to finalize Phase 2 dose in early 2024; End-of-Phase 1 FDA meeting expected H1 2024.
Registrational trial planned for relapsed/refractory WM with 58 patients; top-line data expected mid-2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.